# A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

> **NCT03301207** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 25 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg
- **DRUG:** Bupropion
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT03301207
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2018-07-17
- **Final completion:** 2018-12-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301207, "A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03301207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*